<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03338764</url>
  </required_header>
  <id_info>
    <org_study_id>SM-A-06</org_study_id>
    <nct_id>NCT03338764</nct_id>
  </id_info>
  <brief_title>An Investigational Study to Assess Efficacy and Pattern of Use of SM-1 in Subjects With a History of Transient Insomnia</brief_title>
  <official_title>A Double-Blind, Placebo-Controlled, Parallel Design Phase 3 Study to Assess the Efficacy, Safety, Tolerability, and Pattern of Use of SM-1 in Adult Subjects With a History of Transient Insomnia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sequential Medicine Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sequential Medicine Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the efficacy and pattern of use of the combination
      drug product SM-1 in adults who sometimes have difficulty in falling asleep or staying
      asleep, but who do not have chronic insomnia. Participants will receive SM-1 or placebo to
      take at home as needed over the course of 3 months treatment period.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to assess the efficacy, safety, tolerability and pattern of use
      of SM-1 in adults who sometimes have difficulty in falling asleep or staying asleep, but who
      do not have chronic insomnia. SM-1 is a combination drug product containing diphenhydramine,
      zolpidem and lorazepam. The study is a parallel group design; participants will receive
      either SM-1 or placebo to take at home as needed over the course of 3 months treatment
      period.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2018</start_date>
  <completion_date type="Anticipated">January 2019</completion_date>
  <primary_completion_date type="Anticipated">January 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Subjective Total Sleep Time</measure>
    <time_frame>7 nights</time_frame>
    <description>Total time spent sleeping each night as reported by the subject</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pattern of use</measure>
    <time_frame>3 months</time_frame>
    <description>Subject reported total number of uses and consecutive nights of use</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Adverse Events</measure>
    <time_frame>Through study completion, 17 weeks</time_frame>
    <description>Adverse Events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Residual Effects</measure>
    <time_frame>Through study completion, 17 weeks</time_frame>
    <description>Subject reported answer to the Question, &quot;How alert or sleepy do you feel this morning?&quot; Subjects will rate their alertness on a scale from 0 to 5, with 0 being extremely sleepy and 5 being extremely alert</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Rebound Insomnia</measure>
    <time_frame>Through study completion, 17 weeks</time_frame>
    <description>Total time spent sleeping each night as reported by the subject on night after taking drug or night after not taking drug</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">220</enrollment>
  <condition>Transient Insomnia</condition>
  <arm_group>
    <arm_group_label>Experimental (SM-1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: SM-1 3-drug combination product containing 50-mg diphenhydramine, 5-mg delayed-release zolpidem and 0.5-mg delayed-release lorazepam.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Drug: Placebo Identical in appearance to SM-1 and has the same excipients, but no active ingredients or delayed-release coating materials.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SM-1</intervention_name>
    <description>SM-1 3-drug combination product containing 50-mg diphenhydramine, 5-mg delayed-release zolpidem and 0.5-mg delayed-release lorazepam self-administered as needed to promote sleep</description>
    <arm_group_label>Experimental (SM-1)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Identical in appearance to SM-1 and has the same excipients, but no active ingredients or delayed-release coating materials, self-administered as needed to promote sleep</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Experienced at least 1 prior episode of transient insomnia meeting all of the
             following criteria: difficulty falling asleep or staying asleep; next day impairment
             or distress associated with the disturbed sleep; frequency of 1 to 7 nights per week;
             duration of less than 1 month or more than 1 month of intermittent episodes.

          -  Routinely spends 6.5 - 9.5 hours in bed each night, with bed time varying no more than
             2 hours over a week.

          -  Body Mass Index (BMI) between 19 and 32 kg/m2.

          -  Good general health, as determined by a thorough medical, sleep and psychiatric
             history review, brief physical examination including vital sign measurements, and an
             assessment of screening laboratory test results.

          -  Agrees, for the duration of the study, to take only study drug to address difficulty
             falling asleep or staying asleep, and to not drink alcohol within 2 hours of expected
             bedtime.

        Exclusion Criteria:

          -  Females who are pregnant, breast-feeding, or planning a pregnancy during the study
             period.

          -  Clinically significant medical disorder or currently unstable medical condition that,
             in the opinion of the investigator, would confound the results of the study.

          -  Abnormal laboratory value at screening, judged clinically significant by the
             investigator.

          -  History or current evidence of severe hepatic (liver) impairment.

          -  Clinically significant psychiatric illness, or the history or presence of a major
             psychiatric illness in the past year.

          -  Has a significant risk (in the opinion of the investigator) for suicidal behavior
             during the course of participation in the study or a) At screening: the subject scores
             &quot;yes&quot; on items 4 or 5 in the Suicidal Ideation section of the C-SSRS with reference to
             a 6-month period prior to screening; or b) At screening: the subject has had one or
             more suicidal attempts within a 2-year period prior to screening; or c) At the
             baseline visit: the subject scores &quot;yes&quot; on items 4 or 5 in the Suicidal Ideation
             section of the C-SSRS with reference to screening; or d) The subject is considered to
             be an imminent danger to self or others.

          -  Has a history of chronic insomnia or other sleep disorders, such as sleep apnea,
             narcolepsy, parasomnia, restless leg syndrome, or circadian rhythm disorder.

          -  Has used medications to aid sleep on most nights during the past 2 months.

          -  Has a history of night work or shift work within the month prior to screening or a
             need to participate in night work or shift work during the study.

          -  Has a history of alcohol or substance use disorder within the year prior to screening,
             or current evidence of alcohol or substance use disorder as defined by the Diagnostic
             and Statistical Manual of the American Psychiatric Association, 5th Edition.

          -  Self-report of a usual consumption of more than 14 units of alcohol per week: 1 unit
             of alcohol is equivalent to 12 ounces of beer, 4 ounces of wine, or 1 ounce of liquor.

          -  Has a history of routinely smoking during sleep period.

          -  Has discontinued smoking or participated in a smoking cessation program within 28 days
             of screening, or plans to discontinue smoking during the study.

          -  Has used within 2 weeks or 5 half-lives (whichever is longer) prior to screening of
             any medication that affects sleep-wake function.

          -  Has a positive urine drug screen at the screening visit.

          -  Has a history of allergy or known sensitivity, hypersensitivity, or adverse reaction
             to diphenhydramine, zolpidem, lorazepam, or related compounds.

          -  Has had treatment with any other investigational drug within 28 days or 5 half-lives
             (whichever is longer) prior to screening.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Christal Douglas</last_name>
    <phone>+44 2089911020</phone>
    <email>Christal.Douglas@ppdi.com</email>
  </overall_contact>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 3, 2017</study_first_submitted>
  <study_first_submitted_qc>November 8, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 9, 2017</study_first_posted>
  <last_update_submitted>May 20, 2018</last_update_submitted>
  <last_update_submitted_qc>May 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Transient insomnia</keyword>
  <keyword>Insomnia</keyword>
  <keyword>Sleep initiation and maintenance disorder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Initiation and Maintenance Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diphenhydramine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

